SCHEMBL3338702

SCHEMBL3338702

O=c1[nH]c2ccccc2n2ccc(Br)c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.57
POLB P06746 3/20 0.46
TP53 P04637 2/20 0.45
MAP4K4 O95819 2/20 0.41
TAOK1 Q7L7X3 1/20 0.41
PBK Q96KB5 1/20 0.41
SLK Q9H2G2 1/20 0.41
RXFP1 Q9HBX9 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 3/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41
PDE2A O00408 1/20 0.40
PDE6D O43924 1/20 0.40
PDE8A O60658 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30273110 0.80 PARP1 (0.62) PARP1POLBTP53MAP4K4TAOK1
SCHEMBL3339042 0.73 PDE2A (0.47) PARP1POLBRXFP1ALDH1A1KDM4E
SCHEMBL1133601 0.73 PARP1 (1.00) PARP1POLBTP53MAP4K4TAOK1
SCHEMBL29673205 0.73 PARP1 (1.00) PARP1POLBTP53MAP4K4TAOK1
SCHEMBL3340881 0.70 MAP4K4 (0.58) PARP1POLBTP53MAP4K4TAOK1
SCHEMBL22046026 0.69 PDE2A (0.46) PARP1POLBRXFP1ALDH1A1KDM4E
SCHEMBL7981200 0.68 POLB (0.51) PARP1POLBMAP4K4TAOK1PBK
SCHEMBL2818529 0.67 PDE2A (0.69) PARP1POLBRXFP1ALDH1A1KDM4E
SCHEMBL30273078 0.67 PDE2A (0.69) PARP1POLBRXFP1ALDH1A1KDM4E
SCHEMBL3337877 0.66 PARP1 (0.51) PARP1POLBTP53MAP4K4TAOK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152180-A1 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152180-A1 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) PARP1, PARP2, PARP4 PARP1 1/4885POLB 28/4885TP53 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.